Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ICER Eyes QALY Ratios, Budget Impacts In Methods Review

Executive Summary

Institute for Clinical and Economic Review plans to unveil an updated drug value framework in early 2017.


Related Content

ICER Revising Drug Review Criteria, Will Use Net Prices, Broad Evidence Base
Is ICER Too NICE? A Comparison Of Drug Assessments Programs
Drug Pricing: With "Value" Debate In Full Swing, ICER’s Influence Grows
ICER Atopic Dermatitis Review Prompted By First Biologic
Cost Effectiveness Debate Now Features The Body Bag Argument
ICER Questions Cost Effectiveness Of Empliciti, Kyprolis, Ninlaro
Medicare Value-Pricing Options Vary Widely In Part B Payment Experiment
Scoring Value: New Tools Challenge Pharma's US Pricing Bonanza
PCSK9 List Price Discounts Of 67% To 85% Suggested By ICER Analysis
Hepatitis C Pricing: Insurers' Cost Benchmarks Would Yield Optimal Price Of $42,000 – Report


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts